Conventional chemotherapy for leishmaniasis includes considerably toxic drugs and reports
of drug-resistance are not uncommon. Liposomal encapsulated drugs appear as an option …

In recent decades, nanotechnology has made phenomenal strides in the pharmaceutical
field, favouring the improvement of the biopharmaceutical properties of many active …

Leishmaniasis are a group of neglected infectious diseases caused by protozoa of the
genus Leishmania with distinct presentations. The available leishmaniasis treatment options …

Leishmaniasis is a widespread disease that causes 20,000 to 30,000 deaths annually,
making it a major health problem in endemic areas. Because of low-performance …

The study reported here aimed to develop an optimized nanoparticle delivery system for
amphotericin B (AmpB) using a polyelectrolyte complexation technique. For this, two …

Leishmaniasis is a neglected disease and is endemic in tropical and sub-tropical areas
worldwide. Lifelong immunity after recovery indicates that vaccination could be a promising …

Background Leishmaniasis is a neglected disease, and the current therapeutic arsenal for
its treatment is seriously limited by high cost and toxicity. Nanostructured lipid carriers …

Despite the advancement of new anti-leishmanials, amphotericin B (AmB) prevails as one of
the most potent agent in the treatment of visceral leishmaniasis (VL), a neglected tropical …

Development of an effective drug delivery approach for the treatment of HIV/AIDS is a global
challenge. The conventional drug delivery approaches including Highly Active Anti …

Leishmaniasis is a group of zoonotic diseases caused by a trypanosomatid parasite mostly
in impoverished populations of low-income countries. In their different forms, leishmaniasis …